Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 6Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 2Thoracic 1Gastrointestinal 1

Conditions

Breast Neoplasms 37Neoplasm Metastasis 6Neoplasms 3Ovarian Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Neoplasms by Site 1Medulloblastoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Head and Neck Neoplasms 1HR+/HER2- Breast Cancer 1HER2 Negative Breast Cancer 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1ER+ HER2- Advanced Breast Cancer 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 47Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 15Paclitaxel 14Cyclophosphamide 13Cisplatin 13Carboplatin 13Bevacizumab 12Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Leucovorin 10Irinotecan 10Fluorouracil 10Capecitabine 10trastuzumab deruxtecan 8fludarabine 8Pemetrexed 8Doxorubicin 8Cetuximab 8cemiplimab 7abemaciclib 7Trastuzumab 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × ribociclib × Clear all
NCT07174336 2026-05-22

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Eli Lilly and Company

Phase 3 Recruiting
920 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Celcuity Inc

Phase 3 Recruiting
1,180 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04116541 2026-04-24

MegaMOST

Centre Leon Berard

Phase 2 Recruiting
455 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1 Recruiting
392 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06805812 2025-02-03

PALMARES-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Recruiting
3,500 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡